Condition category
Nutritional, Metabolic, Endocrine
Date applied
14/09/2011
Date assigned
07/10/2011
Last edited
30/11/2012
Prospective/Retrospective
Retrospectively registered
Overall trial status
Completed
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims:
In the last 20 years, in China, calcium supplementation is common and is recommended for postmenopausal women to prevent osteoporosis and improve health. However, until now, there have not been any systematic studies to show the effect of calcium supplements on Chinese women’s health. The aim of this study is to investigate the effect of calcium supplementation on blood glucose, fat levels and obesity in Chinese women.

Who can participate?
Females aged 30 - 60 years with a stable body weight during 6 months before the study.

What does the study involve?
Participants were first sorted by age and then randomly allocated into two groups (calcium supplements group and controlled group). The subjects in the calcium supplements group received a calcium tablet each day to take after supper. Those in the other group took a dummy tablet each day, which looked like the calcium tablet, but did not contain any calcium. This was also to be taken after supper. At the end of the study, participants were asked to provide blood samples to see if these tablets had an effect on the participants’ metabolism on their body and the effect on other body functions.

What are the possible benefits and risks of participating?
Those who received the calcium supplements may be at a lower risk of osteoporosis. There may be bruising and discomfort at the site of the blood test as with any blood test. However, the amounts of blood we took were small enough that they should not cause anaemia or make the subjects feel fatigue.

Where is the study run from?
Department of Nutrition and Food Hygiene, Harbin Medical University.

When is the study starting and how long is it expected to run for?
The study started in December 2008 and ended in December 2009.

Who is funding the study?
Danone Institute China - Diet Nutrition Research and Communication Grant ref: DIC2008-05

Who is the main contact?
Li Ying
liying_helen@163.com

Trial website

Contact information

Type

Scientific

Primary contact

Prof Li Ying

ORCID ID

Contact details

157 Baojian Road
Nangang District
Harbin
150081
China
+86 (0)451 8750 2731
liying_helen@163.com

Additional identifiers

EudraCT number

ClinicalTrials.gov number

Protocol/serial number

N/A

Study information

Scientific title

Effect of calcium supplementation on blood glucose, lipids and obesity in Chinese women: a double-blind, placebo-controlled trial

Acronym

Study hypothesis

A number of studies of calcium supplements on prevention of osteoporosis, weight reduction, improvements in blood glucose and lipids profiles have been researched in the past several decades. However, no definite conclusion was obtained on the effects of calcium supplements on human health. In China, calcium supplementation is prevalent and especially recommended for postmenopausal women to prevent osteoporosis and improve health for the last 20 years. No systematic conclusion of calcium supplements on Chinese women’s health has been obtained so far. We therefore carried out this project to evaluate calcium supplementation on blood glucose, lipids and obesity in Chinese women.

Ethics approval

Medical Ethical Committee of Public Health College, Harbin Medical University approved on 20 November 2008 (ref: 2008013)

Study design

Randomized controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Trial setting

Hospitals

Trial type

Screening

Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Condition

Obesity, blood glucose and lipids

Intervention

Eligible subjects were first sorted by age and then randomized into two groups with a block size of 2, with random numbers generated by statistical software SPSS.

The subjects in the calcium supplements group received a 1500mg calcium carbonate tablet (containing 600mg calcium) 30 minutes after supper once daily.

The subjects in placebo group took a placebo tablet (starch) instead of calcium carbonate at the same times and amounts as in the intervention group. The intervention lasted for 1 year.

Intervention type

Drug

Phase

Not Applicable

Drug names

Calcium carbonate

Primary outcome measures

1. The effects of calcium supplementation on glucose metabolism: fasting glucose and insulin, 2-hour post prandial glucose, Homeostasis Model of Assessment - Insulin Resistance (HOMA-IR) and glycated hemoglobin (HbA1c) (%)
2. The effects of calcium supplementation on lipids metabolism:
2.1. Serum cholesterol, Triglyceride, HDL cholesterol (HDL-C), low-density-lipoprotein cholesterol (LDL-C), apolipoprotein A-I (Apo A-I) and Apolipoprotein B (Apo B)
2.2. Serum lipoprotein lipase (LPL) and adipocyte fatty acid-binding protein (AFABP)
2.3. Serum free fatty acid (FFA) profile
3. The effect on obesity: anthropometric indexes
4. Serum calcium relative indexes, including parathyroid hormone (PTH), 1.25-hydroxyvitamin D3, serum calcium, thyrocalcitonin and serum phosphate

Secondary outcome measures

1. Baseline characteristics: age, gender, body mass index (BMI), blood pressure and physical activity level
2. Daily intake of nutrients by the subjects at baseline and after 1 year intervention
3. Blood biochemistry characteristics of the subjects at baseline and after 1-year intervention: red blood cell, white blood cell, hemoglobin, total protein, albumin, urea nitrogen, creatinine, alanine transaminase and aspartate transaminase

Overall trial start date

16/12/2008

Overall trial end date

15/12/2009

Reason abandoned

Eligibility

Participant inclusion criteria

1. Aged 30-60 years, healthy female
2. Stable body weight during 6 months before the study

Participant type

Patient

Age group

Adult

Gender

Female

Target number of participants

Recruited 400

Participant exclusion criteria

1. A history of cerebrovascular, cardiovascular, renal, hepatic, diabetes, or other medical diseases likely to interfere with the study
2. Taking medications, which were likely to interfere with the study
3. Received calcium supplements at least for one year before the beginning of the study
4. Pregnant or breast-feeding
5. Information incompleted or unwillingness to attempt to comply with the intervention

Recruitment start date

16/12/2008

Recruitment end date

15/12/2009

Locations

Countries of recruitment

China

Trial participating centre

157 Baojian Road
Harbin
150081
China

Sponsor information

Organisation

Harbin Medical University (China)

Sponsor details

c/o Prof Li Ying
Public Health College
157 Baojian Road
Nangang District
Harbin
150081
China
+86 (0)451 8750 2731
liying_helen@163.com

Sponsor type

University/education

Website

http://www.hrbmu.edu.cn/english/index.htm

Funders

Funder type

Research organisation

Funder name

Danone Institute (China) - Diet Nutrition Research and Communication Grant (ref: DIC2008-05)

Alternative name(s)

Funding Body Type

Funding Body Subtype

Location

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes